Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2011-01-25
2011-01-25
Burkhart, Michael (Department: 1633)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C514S002600, C424S001210
Reexamination Certificate
active
07875289
ABSTRACT:
Provided are lipidic particles comprising phosphatidylcholine, phosphatidylinositol and cholesterol. Also provided are compositions comprising the lipidic particles and having associated therewith therapeutic agents such as peptides, polypeptides or proteins. In these compositions, the therapeutic agents have reduced immunogenicity and/or longer circulating time. These compositions can be used for therapeutic administration of the peptides, polypeptides and/or proteins.
REFERENCES:
patent: 4127502 (1978-11-01), Li Mutti et al.
patent: 4795806 (1989-01-01), Brown et al.
patent: 4920016 (1990-04-01), Allen et al.
patent: 5573779 (1996-11-01), Sato et al.
patent: 5580856 (1996-12-01), Prestrelski et al.
patent: 5997864 (1999-12-01), Hart et al.
patent: 6228613 (2001-05-01), Fischer et al.
patent: 6593294 (2003-07-01), Baru et al.
patent: 2002/0098192 (2002-07-01), Whitlow et al.
patent: 2002/0132982 (2002-09-01), Balasubramanian et al.
patent: 2003/0118539 (2003-06-01), Fahl et al.
patent: 2003/0176331 (2003-09-01), Rosenblum et al.
patent: 2004/0229793 (2004-11-01), Balasubramanian et al.
patent: 2004/0229794 (2004-11-01), Ryan et al.
patent: 2006/0246124 (2006-11-01), Pilkiewicz et al.
patent: 2181390 (1997-01-01), None
patent: WO99/55306 (1999-11-01), None
Ramani, et al.; Passive Transfer of Polyethylene glycol to Liposomal-Recombinant Human FVIII Enhances its Efficacy in a Murine Model for Hemophilia A; J. Pharm. Sciences; Feb. 2008 (e pub online); pp. 1-12.
Ramani, et al.; Phosphatidylserine Containing Liposomes Reduce Immunogenicity of Recombinant Human Factor VIII (rFVIII) in a Murine Model of Hemophilia A; J. Pharm. Sciences, Apr. 2008, vol. 97; pp. 1386-1398.
Kirby, et. al.,Preparation of liposomes containing factor VIII for oral treatment of haemophilia. Journal of Microencapsulation, Jan. 1984, vol. 1, pp. 33-45.
Aguilar, et. al.,Phospholipid membranes form specific nonbilayer molecular arrangements that are antigenic, Sep. 1999, Journal of Biological Chemistry, vol. 274, No. 36, pp. 25193-25196.
Manning, et al.,Stability of Protein Pharmaceuticals; Pharmaceutical Research, vol. 6, No. 11, 1989, pp. 903-918.
Balasubramanian, et al.,Liposomes as Formulation Excipients for Protein Pharmaceuticals: A Model Protein Study; Pharmaceutical Research, vol. 17, No. 3, 2000, pp. 344-350.
Braun, et al.,Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing the Antigenicity of Interferon Alpha(IFN-α)in Normal and Transgenic Mice; Pharmaceutical Research, vol. 14, No. 10, 1997, pp. 1472-1478.
Lenting, P.J., et al.,The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein; The Journal of Biological Chemistry, Aug. 1999, vol. 274, No. 34, pp. 23734-23739.
Raut, et al.,Phospholipid binding of factor VIII in different therapeutic concentrates; British Journal of Hematology, 1999, vol. 107, pp. 323-329.
Balu-Iyer Sathy V.
Miclea Razvan
Peng Aaron
Straubinger Robert M.
Burkhart Michael
Hodgson & Russ LLP
The Research Foundation of State University of New York
LandOfFree
Compositions of less immunogenic and long-circulating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions of less immunogenic and long-circulating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions of less immunogenic and long-circulating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2685051